Log in

ContraFect Stock Forecast, Price & News

+0.27 (+5.06 %)
(As of 10/28/2020 12:00 AM ET)
Today's Range
Now: $5.61
50-Day Range
MA: $5.37
52-Week Range
Now: $5.61
Volume115,148 shs
Average Volume261,613 shs
Market Capitalization$156.01 million
P/E RatioN/A
Dividend YieldN/A
ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin, which has completed Phase II clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic influenza infections. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting gram-negative pathogens; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Read More
ContraFect logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CFRX



Sales & Book Value

Annual SalesN/A
Cash Flow$0.64 per share
Book Value$1.01 per share


Net Income$-12,790,000.00


Market Cap$156.01 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
+0.27 (+5.06 %)
(As of 10/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ContraFect (NASDAQ:CFRX) Frequently Asked Questions

How has ContraFect's stock price been impacted by COVID-19?

ContraFect's stock was trading at $6.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CFRX shares have decreased by 19.4% and is now trading at $5.61.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of ContraFect?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ContraFect

When is ContraFect's next earnings date?

ContraFect is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for ContraFect

How were ContraFect's earnings last quarter?

ContraFect Co. (NASDAQ:CFRX) posted its quarterly earnings data on Friday, August, 14th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.14.
View ContraFect's earnings history

When did ContraFect's stock split? How did ContraFect's stock split work?

ContraFect shares reverse split on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2020. An investor that had 100 shares of ContraFect stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CFRX?

4 equities research analysts have issued 12-month price objectives for ContraFect's shares. Their forecasts range from $12.00 to $22.00. On average, they anticipate ContraFect's stock price to reach $16.00 in the next year. This suggests a possible upside of 185.2% from the stock's current price.
View analysts' price targets for ContraFect

Are investors shorting ContraFect?

ContraFect saw a increase in short interest in September. As of September 30th, there was short interest totaling 1,730,000 shares, an increase of 20.1% from the September 15th total of 1,440,000 shares. Based on an average daily trading volume, of 238,200 shares, the short-interest ratio is currently 7.3 days. Approximately 7.1% of the shares of the stock are short sold.
View ContraFect's Short Interest

Who are some of ContraFect's key competitors?

What other stocks do shareholders of ContraFect own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX).

Who are ContraFect's key executives?

ContraFect's management team includes the following people:
  • Dr. Roger James Pomerantz FACP, M.D., F.A.C.P., Chairman, CEO & Pres (Age 63, Pay $1.05M)
  • Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 51, Pay $607.41k)
  • Dr. Cara M. Cassino, Chief Medical Officer and Exec. VP of R&D (Age 58, Pay $848.05k)
  • Mr. Michael Messinger CPA, CPA, Chief Financial Officer (Age 45)
  • Ms. Nancy Dong, VP of Fin. & Admin. (Age 55)

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

Who are ContraFect's major shareholders?

ContraFect's stock is owned by many different institutional and retail investors. Top institutional investors include Usca Ria LLC (0.05%). Company insiders that own ContraFect stock include Cary Sucoff, Fosun Pharmaceutical Shanghai and Michael Messinger.
View institutional ownership trends for ContraFect

Which major investors are buying ContraFect stock?

CFRX stock was purchased by a variety of institutional investors in the last quarter, including Usca Ria LLC. Company insiders that have bought ContraFect stock in the last two years include Cary Sucoff, and Michael Messinger.
View insider buying and selling activity for ContraFect

How do I buy shares of ContraFect?

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $5.61.

How big of a company is ContraFect?

ContraFect has a market capitalization of $156.01 million. The biotechnology company earns $-12,790,000.00 in net income (profit) each year or $1.11 on an earnings per share basis. ContraFect employs 24 workers across the globe.

What is ContraFect's official website?

The official website for ContraFect is www.contrafect.com.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.